EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Kinase Inhibitors: A Promising Approach for Targeted Cancer Therapy

Vishakha Sharma, Ankush Kumar, Rajesh Gour, Kapil Kumar iD

Chemistry & Biodiversity · 2026

DOI: 10.1002/cbdv.202503338 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Vishakha Sharma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Indo-Soviet Friendship College of Pharmacy (ISFCP), Moga, Punjab, India. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 119 Literaturangaben. Gefördert von: University SEED, University of Petroleum and Energy Studies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer develops through unrestrained cell reproduction, which occurs because of genetic alterations, and it leads to 18.1% of fatalities from noninfectious diseases throughout India. The World Health Organization (WHO) and the United Nations Department of Economic and Social Affairs (UNDESA) report that cancer cases will experience substantial growth during the upcoming 20 years. Breast cancer leads to the highest number of female deaths, while lung cancer stands as the most common cause of death for males. The Global Cancer Observatory (GLOBOCAN) reports show that cancer cases increased from 18.1 million in 2018 to about 19 million in 2020. Current therapies have made progress, yet drug resistance and restricted selectivity, together with dangerous side effects, still prevent effective long‐term treatment success. Kinase inhibitors have emerged as a promising class of targeted therapeutics that selectively modulate dysregulated signaling pathways involved in cancer progression. The field lacks a complete and recent evaluation of newly developed kinase inhibitors, which target multiple signaling pathways. The study systematizes and evaluates kinase inhibitors, which target receptor tyrosine kinases (RTKs) and sucrose non‐fermenting‐1/AMP‐activated protein kinase (Snf1/AMPK). The review focuses on recently synthesized molecules (2020–2025) which target major receptors such as EGFR and VEGFR and MELK and acetyl coenzyme A‐related pathways. The work presents a comprehensive summary of recent developments in the field while showing structural activity relationships and pointing out future research paths for anticancer‐based kinase inhibitor development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsAntineoplastic AgentsNeoplasmsHumansReceptor Protein-Tyrosine KinasesSignal TransductionMolecular Targeted TherapyAnimals

Stichwörter der Autor:innen

acetyl coenzyme Acancerkinase inhibitorsmutationsresistancesignaling pathways

Substanzen

Protein Kinase InhibitorsAntineoplastic AgentsReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Indo-Soviet Friendship College of Pharmacy (ISFCP), Moga, Punjab, India.
  • Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
  • School of Pharmacy, LNCT University, Bhopal, Madhya Pradesh, India.
  • Department of Pharmaceutical Sciences, School of Health Sciences and Technology, UPES, Dehradun, Uttarakhand, India.

ORCID-Profile: Kapil Kumar

Förderung

  • University SEED
  • University of Petroleum and Energy Studies

Zitieren

APA

Sharma, V., Kumar, A., Gour, R., & Kumar, K. (2026). Kinase Inhibitors: A Promising Approach for Targeted Cancer Therapy. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202503338

Vancouver

Sharma V, Kumar A, Gour R, Kumar K. Kinase Inhibitors: A Promising Approach for Targeted Cancer Therapy. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.202503338

BibTeX
@article{Sharma2026,
  author = {Sharma, Vishakha and Kumar, Ankush and Gour, Rajesh and Kumar, Kapil},
  title = {Kinase Inhibitors: A Promising Approach for Targeted Cancer Therapy},
  journal = {Chemistry & Biodiversity},
  year = {2026},
  doi = {10.1002/cbdv.202503338}
}
Kostenlos starten →